期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

羟基喜树碱联合方案治疗复发难治性非霍奇金淋巴瘤临床疗效观察

下载PDF
导出
作者 张明智 肖悠美 宋敏 耿丽 李鑫 王瑞林
机构地区 郑州大学第一附属医院肿瘤科
出处 《肿瘤》 CAS CSCD 北大核心 2008年第2期181-182,共2页 Tumor
关键词 淋巴瘤 非霍奇金 喜树碱 预后
分类号 R730.53 [医药卫生—肿瘤]
  • 相关文献

参考文献8

  • 1FISHER R I, GAYNOR E R, DAHLBERG S. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodg, kin s lymphoma [ J ]. N Engl J Med, 1993,328 ( 14 ) : 1002-1006.
  • 2CABANILLAS F. Experience with salvage regimens at M. D. Anderson Hospital[J] .Ann Oncol,1991,2 (Suppl 1 ) :31-32.
  • 3CABALLERO M D, PEREZ-SIMON J A, 1RIONDO A, et al. Highdose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group[J]. Ann Oncol,2003,14( 1 ) :140-151.
  • 4COLEMAN M, LEONARD J, SHUSTER M W, et al. DICE ( dexametha-sone, ifosfamide, cisplatin, etoposide ) infusional chemotherapy for refractory or relapsed non-Hodgkin s lymphoma (NHL) [J]. Eur J Haematol Suppl,2001,64( Suppl ) :41-45.
  • 5VELASQUEZ WS, CABANILLAS F, SALVADOR P,et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone ( DHAP ) [ J ]. Blood, 1988,71(1) :117- 122.
  • 6AURER I, DURAKOVIC N, RADMAN I , et al. Combination of ifosfarrde,methotrexate, and etolide(IMVP) as a salvage therapy for relapsed and refractory aggressive Non -Hodgkin lymphoma: retrospective study [ J ]. Clin Sci ,2002 ;43 ( 5 ) : 550 -554.
  • 7韩维娥,杨斌.羟基喜树碱联合方案治疗难治性恶性淋巴瘤[J].白血病．淋巴瘤,2005,14(3):151-152. 被引量：1
  • 8王锋,钱军,秦叔逵,陈映霞,何泽明,王琳.HEPP方案治疗难治性非霍奇金淋巴瘤的临床观察[J].肿瘤研究与临床,2006,18(3):158-160. 被引量：4

二级参考文献17

  • 1Zelenetz A D, Hamlin P, Kewatramani T, et al. Ifosfamide, carboplatin, etoposicde ( ICE ) -based second-line chemotherapy for the management of relapsed and refractory aggressive non- Hodgkin lymphoma[J]. Ann Oncol, 2003, 14 (suppl 1):5-10.
  • 2Chau I, Harfies M, Cunningham D, et al. Gemcitabine, cisplatin and methylprednisone chemotherapy (GEM-P) is on effective regimen in patients with poor prognostic progressive or multiply relapsed Hodgkin's and non-Hodgkin lymphoma[J]. Br J Heamatol, 2003, 120(6):970-977.
  • 3Sarris A H, Phan A, Goy A, et al. Irinotecan in relapsed or refractory non-Hodgkin's lymphoma. Indications of activity in a phase Ⅱ trial[J].Oncology(Huntingt), 2002, 16(8 Suppl 7):27-31.
  • 4Sugiyama K, Omachi K, Fujiwara K, et al. Irinoteacan hydro-chloride for the treatment of recurrent and refractory non - Hodgkin lymphoma[J]. Cancer, 2002, 94(13):594-600.
  • 5Ribrag V, Koscielny S, Vantelon J M, et al. Phase trial of irinotecan(CPT11) in relapsed or refractory non - Hodgkin lymphoma[J]. Leuk Lmphoma, 2003, 44(9): 1529-1533.
  • 6Yamazaki T, Kura Y, Sawada U. Treatment of intermddiate and high grade non-Hodgkin's lymphoma[J]. Nippon Rinsho, 2000, 58(3): 695-698.
  • 7Plantier C I, Dupriez B, Simon M, et al. The VIM3-Ara-C regimen followed by autologous stem cell transplantation in refractory or relapsing aggressive non-Hoghkin's lymphomas[J]. Leukemia, 1999, 13 (2): 282-288.
  • 8Sarris A H, Romaguera J, Hagemeister F B, et al. Ifinotecan in relapsed or refractory non-Hodgkin's lymphoma [J]. Oncology (Huntingt), 2001,15(7 Suppl 8): 53-56.
  • 9Kraut E H, Balcerzak S P, Young D, et al. A phase Ⅱ study of topotecan in non-Hodgkin's lymphoma: an Ohio State University phase Ⅱ research consortium study[J]. Cancer Invest, 2002, 20(2): 174-179.
  • 10Kancherla R R, Nair J S, Ahmed T, et al. Evaluation of topotecan and etoposide for non-Hodgkin lymphoma: correlation of topoisomeraseDNA complex formation with clinical response[J]. Cancer, 2001, 91 (3): 463-471.

共引文献3

肿瘤
2008年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部